Lefamulin Acetate | ||||
CAS NO.: | 1350636-82-6 | |||
Chemical Formula: | C30H49NO7S | |||
Molecular Weight: | 567.8000 | |||
DMF&GMP status: | Please contact us for more details. | Description: |
Lefamulin is a new and relatively unique antibiotic used for treatment of community acquired pneumonia. Lefamulin has not been linked to an increased rate of transient serum liver test abnormalities during treatment or to instances of clinically apparent liver injury.
**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer. |
|
Approvals | ||||
Active Ingredient | Dosage Form; Route | Strength | Proprietary Name | Applicant |
LEFAMULIN ACETATE | SOLUTION;INTRAVENOUS | EQ 150MG BASE/15ML (EQ 10MG BASE/ML) | XENLETA | NABRIVA THERAPEUTICS IRELAND DAC |
LEFAMULIN ACETATE | TABLET;ORAL | EQ 600MG BASE | XENLETA | NABRIVA THERAPEUTICS IRELAND DAC |
Patent Data | ||||
Patent No. | Patent Expiration | Drug Substance Claim | Drug Product Claim | Patent Use Code |
6753445 | 07/09/2021 | DS | DP | U-2619 |
8071643 | 01/16/2029 | DS | DP | |
8153689 | 03/19/2028 | DS | DP | |
Exclusive Data | ||||
Exclusivity Code | Exclusivity Expiration | |||
NCE | 08/19/2024 | |||
NCE *GAIN | 08/19/2029 | |||